# Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

> **NCT00330733** · PHASE2,PHASE3 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 71 (actual)

## Conditions studied

- Atherosclerosis
- Cardiovascular Disease
- Inflammation
- Insulin Resistance
- Noninsulin-dependent Diabetes Mellitus

## Interventions

- **DRUG:** Salsalate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00330733
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330733, "Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00330733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*